Olema Oncology (OLMA) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Pipeline and trial milestones
Palazestrant, a complete estrogen receptor antagonist with a 14-day half-life, is the lead asset; OPERA-01 monotherapy in 2L/3L is expected to read out in Q1, while 1L OPERA-02 with Kisqali is enrolling well and reads out later.
OP-3136 is a KAT6 inhibitor being studied in breast cancer with fulvestrant and palazestrant; monotherapy activity was also seen in castration-resistant prostate cancer.
OP-3136 with NUBEQA is starting in castration-resistant prostate cancer; earliest data expected by year-end 2027.
OPERA-01 rationale and design
Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in ESR1 wild-type patients; OPERA-01 tests PFS in each population as a separate endpoint.
Management expects a 2–3-month control-arm PFS; eligibility excluded prior chemotherapy in advanced disease and required at least 6 months on the last prior regimen without progression.
Management said a wild-type benefit below 2 months could matter if statistically significant; the trial was powered for a minimally clinically meaningful benefit, with more wild-type than mutant patients supporting detection of a smaller difference.
In ESR1-mutant disease, management cited roughly 2 months of PFS extension as clinically meaningful; greater efficacy could differentiate palazestrant, while oral dosing avoids fulvestrant injections.
Market opportunity and commercial plans
Management estimated the ESR1-mutant market at $2B and ORSERDU sales at $600M–$800M annually, citing persistent unmet need and patients’ preference for oral options that can delay chemotherapy and avoid injections.
If OPERA-01 is positive and enables filing and launch, the U.S. plan is to file and launch; outside the U.S., filing is possible, but launch and promotion would require a collaborator.
Management sees OPERA-01 as potentially establishing the market for OPERA-02, a 1L opportunity it characterized as $10B+.
Latest events from Olema Oncology
- Q1 2027 OPERA-01 readout could test palazestrant in both ESR1 subgroups.OLMA
UBS Global Biopharma Conference 2026 - Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025